However elevated circulating levels of TRX, as observed in metabolic disorders and type 2 diabetes mellitus, have been suggested to reflect a compensatory response to protect against the detrimental effects of TXNIP in an attempt to maintain β-cell function [15], [16], [31], and such mechanisms could also be operating in untreated CS. This evidence concerns the gene TXN and Other metabolic disease.